Beta Bionics (BBNX) awards 91,520 stock options to Chief Commercial Officer

Rhea-AI Filing Summary

Beta Bionics, Inc. reported that Chief Commercial Officer Mark Hopman received an employee stock option grant covering 91,520 shares of common stock. The option has an exercise price of $12.63 per share and expires on February 26, 2036.

The award was granted at no cost on the grant date and vests in 36 equal monthly installments starting on March 1, 2026, reflecting a long-term equity compensation arrangement rather than an open-market share purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$12.63	02/27/2026		A		91,520		(1)	02/26/2036	Common Stock	91,520	$0	91,520	D

Explanation of Responses:

1. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Remarks:

The purpose of this amendment is to correct the number of shares underlying the option grant that was reported on the reporting person's original Form 4 filed with the Securities and Exchange Commission on March 3, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Beta Bionics (BBNX) disclose for Mark Hopman?

Beta Bionics disclosed that Chief Commercial Officer Mark Hopman received an employee stock option grant for 91,520 shares. The options were granted at no cost on grant date, providing the right to buy common stock at a fixed exercise price over time.

What is the exercise price and size of the new BBNX option grant?

The grant gives Mark Hopman options on 91,520 Beta Bionics shares with a fixed exercise price of $12.63 per share. This sets the price at which he can later purchase the company’s common stock if the options vest and are exercised.

How do the Mark Hopman BBNX options vest over time?

The options granted to Mark Hopman vest in 36 equal monthly installments starting March 1, 2026. This means the right to exercise the options builds gradually over three years, encouraging long-term alignment with Beta Bionics’ performance and continued service.

When do the newly granted Beta Bionics (BBNX) options expire?

The employee stock options granted to Mark Hopman expire on February 26, 2036. If any portion is unexercised by that date, those options lapse, limiting the time window during which he can purchase shares at the $12.63 exercise price.

Did Mark Hopman buy or sell any Beta Bionics shares in this Form 4/A?

This filing reflects a grant of employee stock options, not an open-market purchase or sale of shares. Hopman received the options as compensation, and no common stock changed hands yet; actual share acquisitions would occur only if he exercises vested options.

How many derivative securities does Mark Hopman hold after this BBNX grant?

Following this grant, Mark Hopman is reported as holding 91,520 derivative securities in the form of employee stock options. These options represent the right to acquire an equal number of Beta Bionics common shares, subject to vesting and future exercise decisions.